Vericel (VCEL) Profit After Tax Growth (3y) (2013 - 2026)

Vericel (VCEL) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 9.53%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -27.65%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 70.25%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Vericel 2.33 Bn 2.18 Bn 49.27 Mn 5.62%

Historic Data

Download Data
DateValue
Mar 31, 2026 5.62%
Dec 31, 2025 57.70%
Sep 30, 2025 40.47%
Jun 30, 2025 60.49%
Mar 31, 2025 -16.62%
Dec 31, 2024 63.46%
Sep 30, 2024 43.25%
Jun 30, 2024 -7.34%
Mar 31, 2024 -5.50%
Dec 31, 2023 2.07%
Sep 30, 2023 -44.41%
Jun 30, 2023 15.33%
Mar 31, 2023 -16.79%
Dec 31, 2022 -14.58%
Sep 30, 2022 -57.34%
Jun 30, 2022 23.21%
Mar 31, 2022 -35.60%
Dec 31, 2021 -4.71%
Sep 30, 2021 -66.46%
Jun 30, 2021 6.63%